Imbrium Therapeutics

Executive Summary

Imbrium Therapeutics, a subsidiary of Purdue Pharma L.P., is navigating its Chapter 11 reorganization following court approval in November 2025. The company is focused on satisfying conditions for the plan to become effective, at which point it will emerge as Knoa Pharma. Imbrium continues to operate its business, honoring partner and customer obligations. With a Phase 1 stage pipeline centered on small molecules, Imbrium's future hinges on successful emergence from bankruptcy and subsequent execution of its development programs. The reorganization represents a critical inflection point, as the company transitions from restructuring to growth, potentially unlocking value from its pipeline.

Upcoming Catalysts (preview)

• Q2 2026Emergence from Bankruptcy as Knoa Pharma70% success